ACTR3 and AL amyloidosis: As compared with the less studied ACTR3, the potential of ARPC5 as a prognostic biomarker has been investigated in multiple cancer types such as hepatocellular carcinoma (Huang et al., 2021) and multiple myeloma (Xiong and Luo, 2018).